
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6 K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

EDAP TMS S.A. Files

EDAP TMS Communication with Its Investors

July 10-24, 2006

EDAP TMS S.A.

Parc Activite La Poudrette Lamartine

4/6 Rue du Dauphine

69120 Vaulx-en-Velin - France

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

EDAP TMS Investor Summary

The Global Leader in HIFU for Localized Prostate Cancer

This presentation contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission, including under "Forward-Looking Information", "Risk Factors" and "Operating and Financial Review and Prospects" in the Company's 2005 annual report on Form 20-F.

Philippe Chauveau
Chairman

Hugues de Bantel
Chief Executive Officer

July 2006



1

[Link to searchable text of Slide Shown above](#)



Nasdaq : EDAP

Business

Therapeutic ultrasound

Strategy

Address growing demand for **non-invasive** therapies using therapeutic ultrasound based on 25 year successful track record in **marketing innovative technologies**

Shares Outstanding Basic	7.8 million
Shares Outstanding Diluted	8.6 million
Share price as of July 3rd	\$10.25
Avg. daily volume (3 months)	146,593 shares
Annual revenue (12/31/05)	\$26 million
Cash (3/31/06)	\$9.2 million
Debt (12/31/05)	\$1.3 million





Addressing two major pathologies in Urology:

Prostate Cancer

using HIFU
A growing market



Kidney Stones

using Lithotripsy
A stable and predictable business




edap tms
Bringing New Horizons to Therapy

[Link to searchable text of Slide Shown above](#)




Prostate Gland



edap tms
Bringing New Horizons to Therapy

Prostate Cancer: The most common male specific cancer

- 238,000 new cases per year in Europe**; 231,000 in the USA*
- In Europe, 70% of new cases (160,000) are localized T1 or T2 cancer stages – HIFU candidates



➔ **EDAP targeting 160,000+ patients in Europe
Currently Treating ~ 2% (~2,800) of the target**

The prostate cancer patient is today:

- Better educated about the risk of side effects, recurrence and operator variance in traditional therapies,
- More likely to desire a better treatment option, and
- Including Quality of Life as a primary factor in his treatment decision



Bringing New Horizons to Therapy

* (Source: 2004 American Cancer Society)
** (Source: 2004, International Agency for Research on Prostate Cancer)



Ablatherm® Brings a New Standard of Care to Prostate Cancer

EDAP is committed to:

- Offer patients the **best** combination of efficacy and safety
- Fully **enlighten** patients about existing treatment options
- Preserve patient **quality of life**

Ablatherm-HIFU is proven to:

- Provide **consistently** high success without operator skill variability
- Offer **lower** side effects and a **rapid** recovery
- Treat without precluding other therapy if cancer **recurs** in the future
- Treat difficult recurrence cases often at an impasse under **traditional therapies**




Bringing New Horizons to Therapy

6


[Link to searchable text of Slide Shown above](#)

Ablatherm-HIFU a Proven Option

- The recognized **Global Leader** in HIFU for prostate cancer
- Fully **Approved** in Europe, Canada, Russia, Australia, South East Asia, etc.
- More than **10,000 treatments** and **105 sites** worldwide
- In excess of **100 publications and posters**
- Already **reimbursed** in Germany & Italy (up to €4,500) and privately in the UK (initiated at approx. £11,000), pursuing reimbursements in France and other markets
- US **FDA Trials** in progress with HealthTronics
- **56 HIFU patents**



Ablatherm-HIFU Favorable Benefits




Ablatherm-HIFU offers:

- Efficacy as good as current therapies
- Low side effect risks to the patient
- Rapid recovery after treatment

Ablatherm-HIFU offers patients an opportunity to preserve their quality of life after treating prostate cancer

Ablatherm®-HIFU Favorable Benefits

Favorable Disease Free Rate^(*) at 5 years for low & intermediate risk cancers



Ablatherm-HIFU offers:

- Predictable outcomes
- No operator dependence
- No impasse: repeatable

The patient can have confidence in HIFU as a low risk option for initial treatment

Once **aware** of HIFU, the patient can see this as a very attractive choice.

* Clinical disease free rate is defined as being biochemical (PSA) without evidence of disease at last follow-up.

Sources: Nature Clinical Practice, April 2003, Vol. 2, No. 4 / Progres en Urologie (2003), 13, 1428-1436, P C RI Insights Feb. 2003, Vol. 8, No. 1, Urology 2004 Feb 63(2)

HIFU as a robotic technique offers consistent success between users reducing operator skill concerns



Bringing New Horizons to Therapy

[Link to searchable text of Slide Shown above](#)




Ablatherm Preserves Patient Quality of Life: Lower Side Effects


Recto-urethral fistula



Urinary incontinence (Grade 2 to 3)



Sexual Impotence




edap tms

Bringing New Horizons to Therapy

[Link to searchable text of Slide Shown above](#)

Favorable HIFU Economics for Physicians and Clinics



Ablatherm-HIFU offers*:

- **Rapid** learning in just 10 sessions
- **Short** treatment time increases facility efficiency
- **Fewer** staff hours per session lowers personnel expenses
- **Broad** indication range makes applicable to large patient population
- Capital **free** RPP model offers access without financial risks



Bringing New Horizons to Therapy

*Source: S. Thuroff, C. Choussy: Prostate Cancer Treatment Costs: What Influences Them? EAU Poster 1036, 2006

11

[Link to searchable text of Slide Shown above](#)

Benefits to the Patients

- Minimally invasive and proven therapy that can better preserve **quality of life**
- Can enable rapid **return to normal** activity
- Highly **reproducible efficacy** / Treatment can be **repeated** if needed

Benefits to the Surgeons

- **Minimally invasive** solution that meets patient demands
- **Recapture** marketshare from nonsurgical therapies (~50% of market)
- New Gold Standard for **treating radiation failures**

Benefits to the Hospitals

- Drive **incremental** patient traffic
- Immediate **return** through Revenue-Per-Procedure (**RPP**) model

Benefits to the Healthcare systems

- **Lower associated costs** than existing therapies, **shorter** hospital stay
- **Lower follow-up** care required for recovery, side effects or recurrence





RPP Model: The Growth Opportunity

EDAP is Transitioning from Its Straight Machine Sales Model...



Ablatherm Unit sold
€ 500,000* list price
Typically Centers treating
> 60 patients annually



Yearly Service Agreement*
€ 45,000



Disposable Ablapack*
€ 550

- Unit sales represent **large** revenue blocks
- EDAP earns **recurring** & **predictable** services & disposable revenues
- European centers have **limited capital** budgets
- Centers must treat **larger** populations annually

HIFU Service & Disposable Revenues (€000s)



* List price as of Dec. 31, 2005




Bringing New Horizons to Therapy


[Link to searchable text of Slide Shown above](#)

RPP Model: The Growth Opportunity

... To Recurring Treatment Procedures Sales Model



HIFU Treatment /
Revenue-per-
procedure (RPP)*
€ 2,800




- Increased Use
- Clear Returns
- Grows Market
- Generates BUZZ

RPP has a higher lifetime revenue and profit potential to EDAP:

- RPP **quickly** allows centers to adopt HIFU
- RPP **removes** financial risk to the center
- RPP revenues are already **accelerating** from broader market penetration
- **Lower initial** revenues & cash flows

RPP Treatment Revenues (€ 000s)



➔ Expand RPP Business

- Rapidly place more EDAP owned machines with no capital required from hospital and a clear pay back to EDAP
- Provide support to increase use of equipment in marketplace: patient education and medical marketing

➔ Education: Increase Patient Demand

- Increase patient awareness driving demand **(PULL)**
- Direct patients to HIFU centers in reimbursed countries
- Create community buzz with help of media, thought leaders, advocates and word of mouth

➔ Accelerate Hospital & Urologist Adoption

- Patient demand makes HIFU a necessary offering **(PUSH)**
- Further HIFU as a standard of care for first indication
- Lock HIFU as the Gold Standard for radiation failures
- Once available at site, grow use beyond site plans

HIFU success measures:

- Total sites
- Total treatments

Increasing sites and treatments leads to growing revenues and scalable profitability



Bringing New Horizons to Therapy

Marketing: Put the Patient in the Center of the Communication





Telling the HIFU Story to Patients

- Improve patient awareness about **Quality of Life factors** in treatment
- Show patients that **bloodless and radiation-free** non-invasive surgery of the future is already available
- Inform patients this new technique is the best combination of **efficacy and safety**
- Explain to patients that a technique which is safe, efficient, fast, non-invasive, reliable, painless, and based on high technology is the **best solution** for them
- Tell patients that treatments are increasing quickly and **more centers** are opening
- Give **new hope** to those numerous patients with recurrence after EBRT for whom there are no **salvage therapies** as efficient as HIFU
- Present complete and thorough material so patients can make a **fully informed** choice



Telling the HIFU Story to Medical Professionals

- **Demonstrate** the clinical success and confirmed **low side effects** in peer literature
- Continue promoting HIFU in urology through **leaders** in every country
- Further advance the medical consensus on first indication and radiation failure cases as the **new standard of care**
- Promote Ablatherm within “medical standards” to create credibility and **open doctor minds** to a new treatment choice with real benefits
- Continue **best-in-class training** program with experienced practitioner pairings to ensure rapid achievement of Ablatherm proficiency in just 10 to 12 treatments
- Market **CAPITAL-FREE** launch choices removing financial risk for new clinical sites launching Ablatherm care
- Promote the **business benefits** of Ablatherm in building the clinic’s patient revenues by winning incremental treatments over competing centers



The Next Milestone: 5% of Targeted European Patients

European Market Scope:

- 160,000 localized prostate cancer HIFU candidates diagnosed yearly
- Growing market share builds credibility and increases demand
- Next milestone: EDAP Ablatherm-HIFU treats 8,000 patients / year = 5% market share
- Current run rate is 2,800 patients / year
- New marketing and broader market penetration position EDAP to gain share

	Straight Unit Sales Model (all machines sold)	RPP Model		Total
		RPP Fixed Site Model	RPP Mobile Sites Model	
Targeted total cum. # of treating sites	60	40	140	240
Targeted total cum. # of machines	60	40	20	120
Targeted # of treatments / site / year	60	40	20	--
Targeted total cum. # of treatments / yr	3,600	1,600	2,800	8,000



Bringing New Horizons to Therapy



Incremental Growth Drivers

Additional reimbursement approvals including more UK plans and the French National Health Plan are being secured. Approval of reimbursement has a demonstrated acceleration effect on treatment rates and site launches.


Launches in new markets are ongoing where Ablatherm-HIFU is approved with or without reimbursement. Recent launches have demonstrated accelerated success from EDAP's clinical strength already proven in Europe. Increasingly, the company is using the RPP model to accelerate adoption by key thought leaders.

USA Clinical Phase II/III Studies are now in progress for future USA approval. Recruitment is ongoing at multiple sites comparing HIFU to cryo. HTRN, the largest urology services company in the USA, is conducting the studies and will have USA distribution rights upon successful FDA approval.



EDAP TMS : A World LEADER in
NON INVASIVE
Treatment Techniques Using THERAPEUTIC ULTRASOUND

Urinary stones





Lithotripsy: A Recurrent & Strong Business

Current Worldwide Installed Base > 3,000 Units

Replacement Market > 300 Units / Year @ average \$250,000 (= \$75M / Year)*

EDAP is a leader in Asia, including Japan, and Europe due to customer proximity and provided services

Market Drivers:

- Service Capacity, Credibility & Proximity
- Technology
- Global reach

Predictable Service & Consumables Revenue @ 8-10% of equipment sales


Sales & Service Experience opens market to the Ablathem-HIFU model



[Link to searchable text of Slide Shown above](#)



Distribution of Global Lithotripsy Market: EDAP Installed Unit Base*



Global Total:
3000 litho units
EDAP Total:
416 litho units



edap tms
Bringing New Horizons to Therapy

* Company's figures of Dec. '05

Financials





EDAP – HIFU Division: Euro 000s*

Period	Revenue	Gross Margin	Op. Income
Q1 2006	1,949	56%	1
2005	7,949	50%	135
2004	6,969	46%	387

TMS – UDS (Lithotripsy) Division: Euro 000s*

Period	Revenue	Gross Margin	Op. Income
Q1 2006	3,863	31%	(66)
2005	16,154	29%	243
2004	17,385	30%	184



Bringing New Horizons to Therapy

* EDAP markets and sells Ablatherm®; TMS does all manufacturing and markets and sells Lithotripsy; See 20F for complete details

25

[Link to searchable text of Slide Shown above](#)

Income Statement

Euro 000s except per share	Q1 2006	2005	2004	2003
INCOME STATEMENT DATA				
Total revenues	5,199	20,810	22,163	18,473
Total net sales	5,184	20,717	21,955	18,030
Gross profit	2,286	8,497	8,487	5,379
Operating expenses	(2,770)	(9,820)	(9,317)	(13,500)
Loss from operations	(484)	(1,323)	(830)	(8,121)
Income (loss) before income taxes	(546)	(961)	(871)	(9,090)
Income tax (expense) benefit	(77)	(104)	(278)	114
Net income (loss)	(623)	(1,065)	(1,149)	(8,976)
Basic earnings (loss) per share	(0.08)	(0.14)	(0.15)	(1.15)
Weighted average basic shares	7,823,331	7,782,731	7,781,731	7,781,731
Weighted average diluted shares	8,608,255	8,373,574	8,074,210	7,817,303



Balance Sheet

<small>Euro 0 00s</small>	March 31, 2006 Euros	December 31, 2005 Euros
Cash, cash equivalents and short term investments	7,591	8,317
Total current assets	21,846	22,034
Total current liabilities	9,675	9,557
Shareholders' Equity	16,871	17,372



edap tms
Bringing New Horizons to Therapy



The EDAP Outlook

- Grow **HIFU business** by deploying infrastructure for the **RPP model** facilitating access to Ablatherm-HIFU therapy at centers of excellence and regional centers in Europe
- Develop **dedicated PR programs** for each major site (sold or RPP) to assist hospitals and surgeons in the promotion of the Ablatherm-HIFU
- Dramatically **increase patient awareness** on the compelling benefits of Ablatherm-HIFU by rolling out an **aggressive marketing** campaign in Europe
- Add to long-term clinical studies and publications to **further broaden the adoption** of Ablatherm-HIFU by the medical community, **approval** authorities and **reimbursement** officials in major markets
- Further refine Ablatherm-HIFU applied to prostate cancer constantly striving at enhancing **patient quality of life**
- Further expand EDAP's **HIFU product portfolio and IP** in prostate cancer and other pathologies



The Global Leader in HIFU for Localized Prostate Cancer

This presentation contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission, including under "Forward-Looking Information", "Risk Factors" and "Operating and Financial Review and Prospects" in the Company's 2005 annual report on Form 20-F.

Philippe Chauveau
Chairman

Hugues de Bantel
Chief Executive Officer

July 2006

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

EDAP at a Glance

Nasdaq : EDAP

Business

Therapeutic ultrasound

Strategy

Address growing demand for **non-invasive** therapies using therapeutic ultrasound based on 25 year successful track record in **marketing innovative technologies**

Shares Outstanding Basic	7.8 million
Shares Outstanding Diluted	8.6 million
Share price as of July 3rd	\$10.25
Avg. daily volume (3 months)	146,593 shares
Annual revenue (12/31/05)	\$26 million
Cash (3/31/06)	\$9.2 million
Debt (12/31/05)	\$1.3 million

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

EDAP TMS: The Global Leader in Therapeutic Ultrasound

Addressing two major pathologies in Urology:

Prostate Cancer

using HIFU

A growing market

[GRAPHIC APPEARS HERE]

Kidney Stones

using Lithotripsy

A stable and predictable business

[GRAPHIC APPEARS HERE]

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

HIFU for Localized Prostate Cancer

Prostate Gland

[GRAPHIC APPEARS HERE]

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

Global Prostate Cancer Market

Prostate Cancer: The most common male specific cancer

- 238,000 new cases per year in Europe**; 231,000 in the USA*
- In Europe, 70% of new cases (160,000) are localized T1 or T2 cancer stages – HIFU candidates

[CHART APPEARS HERE]

EDAP targeting 160,000+ patients in Europe Currently Treating ~ 2% (~2,800) of the target

The prostate cancer patient is today:

- Better educated about the risk of side effects, recurrence and operator variance in traditional therapies,
- More likely to desire a better treatment option, and
- Including Quality of Life as a primary factor in his treatment decision

* (Source: 2004 American Cancer Society)

** (Source: 2004, International Agency for Research on Prostate Cancer)

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

Ablatherm® Brings a New Standard of Care to Prostate Cancer

EDAP is committed to:

- Offer patients the **best** combination of efficacy and safety
- Fully **enlighten** patients about existing treatment options
- Preserve patient **quality of life**

Ablatherm-HIFU is proven to:

- Provide **consistently** high success without operator skill variability
- Offer **lower** side effects and a **rapid** recovery
- Treat without precluding other therapy if cancer **recurs** in the future
- Treat difficult recurrence cases often at an impasse under **traditional therapies**

[GRAPHIC APPEARS HERE]

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

Ablatherm-HIFU a Proven Option

- The recognized **Global Leader** in HIFU for prostate cancer
- Fully **Approved** in Europe, Canada, Russia, Australia, South East Asia, etc.
- More than **10,000 treatments** and **105 sites** worldwide
- In excess of **100 publications and posters**
- Already **reimbursed** in Germany & Italy (up to €4,500) and privately in the UK (initiated at approx. £11,000), pursuing reimbursements in France and other markets
- US **FDA Trials** in progress with HealthTronics
- **56 HIFU patents**

[GRAPHIC APPEARS HERE]

[GRAPHIC APPEARS HERE]

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

Ablatherm-HIFU Favorable Benefits

Ablatherm-HIFU offers:

[CHART APPEARS HERE]

- Efficacy as good as current therapies
- Low side effect risks to the patient
- Rapid recovery after treatment

Ablatherm-HIFU offers patients an opportunity to preserve their quality of life after treating prostate cancer

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

Ablatherm®-HIFU Favorable Benefits

Favorable Disease Free Rate^(*) at 5 years
for low & intermediate risk cancers

[CHART APPEARS HERE]

Ablatherm-HIFU offers:

- Predictable outcomes
- No operator dependence
- No impasse: repeatable

The patient can have confidence in HIFU as a low risk option for initial treatment

Once **aware** of HIFU, the patient can see this as a very attractive choice.

** Clinical disease free rate is defined as being biochemical (PSA) without evidence of disease at last follow-up.*

Sources: Nature Clinical Practice, April 2005, Vol. 2 No.4 /
Progres en Urologie (2003), 13 1428-1456, PCRI Insights Feb.
2005 Vol. 8, No. 1, Urology 2004 Feb 63(2)

HIFU as a robotic technique offers consistent success between users reducing operator skill concerns

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

Ablatherm-HIFU Favorable Benefits

Ablatherm Preserves Patient Quality of Life: Lower Side Effects

Recto-urethral fistula

[CHART APPEARS HERE]

Source:
NCI, Pubmed + PCRI Insights
Feb, 2005 Vol. 8, No.1

Urinary incontinence (Grade 2 to 3)

[CHART APPEARS HERE]

Sources: Complete review of NCI,
Pubmed, PCRI Insights Feb 2005
Vol.8, No1, Urology 60, 2002

Sexual Impotence

[CHART APPEARS HERE]

Sources: PCRI Insights Feb. 2005
Vol. 8, No. 1, Monocentric
prospective study assessing
potency post HIFU (submitted at
AFU 2006), Nature Clinical
Practice, April 2005, Vol. 2 No.4

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

Favorable HIFU Economics for Physicians and Clinics

[CHART APPEARS HERE]

Ablatherm-HIFU offers*:

- **Rapid** learning in just 10 sessions
- **Short** treatment time increases facility efficiency
- **Fewer** staff hours per session lowers personnel expenses
- **Broad** indication range makes applicable to large patient population
- Capital **free** RPP model offers access without financial risks

* Source: S. Thuroff, C Chaussy: Prostate Cancer Treatment Costs: What Influences Them?, EAU Poster 1036, 2006

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

Ablatherm-HIFU: An attractive Choice to all Parties

Benefits to the Patients

- Minimally invasive and proven therapy that can better preserve **quality of life**
- Can enable rapid **return to normal** activity
- Highly **reproducible efficacy** / Treatment can be **repeated** if needed

Benefits to the Surgeons

- **Minimally invasive** solution that meets patient demands
- **Recapture** marketshare from nonsurgical therapies (~50% of market)
- New Gold Standard for **treating radiation failures**

[GRAPHICS APPEAR HERE]

Benefits to the Hospitals

- Drive **incremental** patient traffic
- Immediate **return** through Revenue-Per-Procedure (**RPP**) model

Benefits to the Healthcare systems

- **Lower associated costs** than existing therapies, **shorter** hospital stay
- **Lower follow-up** care required for recovery, side effects or recurrence

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

RPP Model: The Growth Opportunity

EDAP is Transitioning from Its Straight Machine Sales Model...

[GRAPHIC APPEARS HERE]

Ablatherm Unit sold
€ 500,000* list price
Typically Centers treating
> 60 patients annually

[GRAPHIC APPEARS HERE]

Yearly Service
Agreement*
€ 45,000

[GRAPHIC APPEARS HERE]

Disposable
Ablapack*
€ 550

HIFU Service & Disposable Revenues (€000s)

- Unit sales represent **large** revenue blocks
- EDAP earns **recurring & predictable** services & disposable revenues
- European centers have **limited capital** budgets
- Centers must treat **larger** populations annually

[CHART APPEARS HERE]

* List price as of Dec. 31, 2005

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

RPP Model: The Growth Opportunity

...To Recurring Treatment Procedures Sales Model

[GRAPHIC APPEARS HERE]

EDAP Owns Ablatherm Unit
Center Pays Per Use
Fixed if >40 patients per year
Mobile if <40 patients per year

[GRAPHIC APPEARS HERE]

[GRAPHIC APPEARS HERE]

HIFU Treatment /
Revenue-per-
procedure (RPP)*
€ 2,800

- Increased Use
- Clear Returns
- Grows Market
- Generates Buzz

RPP has a higher lifetime revenue and profit potential to EDAP:

- RPP **quickly** allows centers to adopt HIFU
- RPP **removes** financial risk to the center
- RPP revenues are already **accelerating** from broader market penetration
- **Lower initial** revenues & cash flows

RPP Treatment Revenues (€ 000s)

[CHART APPEARS HERE]

* List price as of Dec. 31, 2005

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

RPP Model: Capturing the Growth Opportunity

Expand RPP Business

- Rapidly place more EDAP owned machines with no capital required from hospital and a clear pay back to EDAP
- Provide support to increase use of equipment in marketplace: patient education and medical marketing

Education: Increase Patient Demand

- Increase patient awareness driving demand (PULL)
- Direct patients to HIFU centers in reimbursed countries
- Create community buzz with help of media, thought leaders, advocates and word of mouth

Accelerate Hospital & Urologist Adoption

- Patient demand makes HIFU a necessary offering (PUSH)
- Further HIFU as a standard of care for first indication
- Lock HIFU as the Gold Standard for radiation failures
- Once available at site, grow use beyond site plans

HIFU success measures:

- Total sites
- Total treatments

Increasing sites and treatments leads to growing revenues and scalable profitability

[GRAPHICS APPEAR HERE]

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

Telling the HIFU Story to Patients

- Improve patient awareness about **Quality of Life factors** in treatment
- Show patients that **bloodless and radiation-free** non-invasive surgery of the future is already available
- Inform patients this new technique is the best combination of **efficacy and safety**
- Explain to patients that a technique which is safe, efficient, fast, non-invasive, reliable, painless, and based on high technology is the **best solution** for them
- Tell patients that treatments are increasing quickly and **more centers** are opening
- Give **new hope** to those numerous patients with recurrence after EBRT for whom there are no **salvage therapies** as efficient as HIFU
- Present complete and thorough material so patients can make a **fully informed** choice

Telling the HIFU Story to Medical Professionals

- **Demonstrate** the clinical success and confirmed **low side effects** in peer literature
- Continue promoting HIFU in urology through **leaders** in every country
- Further advance the medical consensus on first indication and radiation failure cases as the **new standard of care**
- Promote Ablatherm within “medical standards” to create credibility and **open doctor minds** to a new treatment choice with real benefits
- Continue **best-in-class training** program with experienced practitioner pairings to ensure rapid achievement of Ablatherm proficiency in just 10 to 12 treatments
- Market **CAPITAL-FREE** launch choices removing financial risk for new clinical sites launching Ablatherm care
- Promote the **business benefits** of Ablatherm in building the clinic’s patient revenues by winning incremental treatments over competing centers

The Next Milestone: 5% of Targeted European Patients

European Market Scope:

- 160,000 localized prostate cancer HIFU candidates diagnosed yearly
- Growing market share builds credibility and increases demand
- Next milestone: EDAP Ablatherm-HIFU treats 8,000 patients / year = 5% market share
- Current run rate is 2,800 patients / year
- New marketing and broader market penetration position EDAP to gain share

	Straight Unit Sales Model (all machines sold)	RPP Model		Total
		RPP Fixed Site Model	RPP Mobile Sites Model	
Targeted total cum. # of treating sites	60	40	140	240
Targeted total cum. # of machines	60	40	20	120
Targeted # of treatments / site / year	60	40	20	—
Targeted total cum. # of treatments/yr	3,600	1,600	2,800	8,000

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

Incremental Growth Drivers

Additional reimbursement approvals including more UK plans and the French National Health Plan are being secured. Approval of reimbursement has a demonstrated acceleration effect on treatment rates and site launches.

Launches in new markets are ongoing where Ablatherm-HIFU is approved with or without reimbursement. Recent launches have demonstrated accelerated success from EDAP's clinical strength already proven in Europe. Increasingly, the company is using the RPP model to accelerate adoption by key thought leaders.

USA Clinical Phase II/III Studies are now in progress for future USA approval. Recruitment is ongoing at multiple sites comparing HIFU to cryo. HTRN, the largest urology services company in the USA, is conducting the studies and will have USA distribution rights upon successful FDA approval.

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

**EDAP TMS : A World LEADER in
NON INVASIVE
Treatment Techniques Using THERAPEUTIC ULTRASOUND**

Urinary stones

[GRAPHIC APPEARS HERE]

[GRAPHIC APPEARS HERE]

Lithotripsy: A Recurrent & Strong Business

Current Worldwide Installed Base > 3,000 Units

Replacement Market > 300 Units / Year @ average \$250,000 (= \$75M / Year)*

EDAP is a leader in Asia, including Japan, and Europe due to customer proximity and provided services

Market Drivers:

- Service Capacity, Credibility & Proximity
- Technology
- Global reach

Predictable Service & Consumables Revenue @ 8-10% of equipment sales

Sales & Service Experience opens market to the Ablatherm-HIFU model

* Company's estimates

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

Lithotripsy Market

Distribution of Global Lithotripsy Market: EDAP Installed Unit Base*

[GRAPHIC APPEARS HERE]

Global Total:
3000 litho units

EDAP Total:
416 litho units

* Company's figures at Dec. '05

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

Division Performance**EDAP – HIFU Division: Euro 000s***

Period	Revenue	Gross Margin	Op. Income
Q1 2006	1,949	56%	1
2005	7,949	50%	135
2004	6,969	46%	387

TMS – UDS (Lithotripsy) Division: Euro 000s*

Period	Revenue	Gross Margin	Op. Income
Q1 2006	3,863	31%	(66)
2005	16,154	29%	243
2004	17,385	30%	184

* EDAP markets and sells Ablatherm®; TMS does all manufacturing and markets and sells Lithotripters; See 20F for complete details

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

Income Statement

Euro 000s except per share	Q1 2006	2005	2004	2003
INCOME STATEMENT DATA				
Total revenues	5,199	20,810	22,163	18,473
Total net sales	5,184	20,717	21,955	18,030
Gross profit	2,286	8,497	8,487	5,379
Operating expenses	(2,770)	(9,820)	(9,317)	(13,500)
Loss from operations	(484)	(1,323)	(830)	(8,121)
Income (loss) before income taxes	(546)	(961)	(871)	(9,090)
Income tax (expense) benefit	(77)	(104)	(278)	114
Net income (loss)	(623)	(1,065)	(1,149)	(8,976)
Basic earnings (loss) per share	(0.08)	(0.14)	(0.15)	(1.15)
Weighted average basic shares	7,823,331	7,782,731	7,781,731	7,781,731
Weighted average diluted shares	8,608,255	8,373,574	8,074,210	7,817,303

[LOGO OF EDAP TMS]

Bringing New Horizons to Therapy

Balance Sheet

Euro 000s	March 31, 2006 Euros	December 31, 2005 Euros
Cash, cash equivalents and short term investments	7,591	8,317
Total current assets	21,846	22,034
Total current liabilities	9,675	9,557
Shareholders' Equity	16,871	17,372

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

The EDAP Outlook

- Grow **HIFU business** by deploying infrastructure for the **RPP model** facilitating access to Ablatherm-HIFU therapy at centers of excellence and regional centers in Europe
- Develop **dedicated PR programs** for each major site (sold or RPP) to assist hospitals and surgeons in the promotion of the Ablatherm-HIFU
- Dramatically **increase patient awareness** on the compelling benefits of Ablatherm-HIFU by rolling out an **aggressive marketing** campaign in Europe
- Add to long-term clinical studies and publications to **further broaden the adoption** of Ablatherm-HIFU by the medical community, **approval** authorities and **reimbursement** officials in major markets
- Further refine Ablatherm-HIFU applied to prostate cancer constantly striving at enhancing **patient quality of life**
- Further expand EDAP's **HIFU product portfolio and IP** in prostate cancer and other pathologies

[LOGO OF EDAP TMS]
Bringing New Horizons to Therapy

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date : July 25, 2006

EDAP TMS S.A.

/s/ HUGUES DE BANTEL

HUGUES DE BANTEL
CHIEF EXECUTIVE OFFICER
